A three-member investigation team from the State Food and Drug
Administration (SFDA) is conducting a thorough probe into a
problematic injection that has suspiciously killed three and
sickened 78 others across the country.
An official with the provincial food and drug administration
said Monday that the team arrived over the weekend at the Anhui
Huayuan Worldbest Biology Pharmacy Co., producer of the injection,
in east China's Anhui Province, to carry out the
investigation.
The team will investigate raw and supplementary materials of the
injection, production process, and examination process for finished
products, the official said.
Eighty-one cases of severe reaction in ten provinces, including
three deaths, after the use of the drug, clindamycin phosphate
glucose injection used to treat bacterial infections, had been
reported, according to the Adverse Drug Reaction Monitoring Center
of the SFDA.
The Ministry of Health had issued an urgent circular last week
ordering the suspension of using the antibiotic injection produced
by the Anhui company since June.
(Xinhua News Agency August 7, 2006)
